Comparison of the Efficacy and Safety of Irbesartan and Olmesartan in Patients With Hypertension (EARTH Study)

REFERENCES

• de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52:415–472.
   PubMed Web of Science ®Google Scholar
• Miura S, Saku K, Karnik SS. Molecular analysis of the structure and function of the angiotensin II type 1 receptor. Hypertens Res 2003; 26:937–943.
   PubMed Web of Science ®Google Scholar
• Miura S, Karnik SS, Saku K. Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects. J Renin Angiotensin Aldosterone Syst 2011; 12:1–7.
   PubMed Web of Science ®Google Scholar
• Yamada S, Ano N, Toda K, . Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro. Hypertens Res 2008; 31:601–606.
   PubMed Web of Science ®Google Scholar
• Picca M, Agozzino F, Pelosi G. Effects of losartan and valsartan on left ventricular hypertrophy and function in essential hypertension. Adv Ther 2004; 21:76–86.
   PubMed Web of Science ®Google Scholar
• Miura S, Saku K. Do angiotensin II type 1 receptor blockers have molecular effects? Hypertens Res 2010; 33:105–106.
   PubMed Web of Science ®Google Scholar
• Iwata A, Miura S, Imaizumi S, . Do valsartan and losartan have the same effects in the treatment of coronary artery disease? Circ J 2007; 71:32–38.
   PubMed Web of Science ®Google Scholar
• Sugihara M, Miura S, Takamiya Y, . Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation. Hypertens Res 2009; 32:625–630.
   PubMed Web of Science ®Google Scholar
• Kiya Y, Miura S, Fujino M, Imaizumi S, Karnik SS, Saku K. Clinical and pharmacotherapeutic relevance of the double-chain domain of the angiotensin II type 1 receptor blocker olmesartan. Clin Exp Hypertens 2010; 32:129–136.
   PubMed Web of Science ®Google Scholar
• Miura S, Fujino M, Saku K. Angiotensin II receptor blocker as an inverse agonist: a current perspective. Curr Hypertens Rev 2005; 1:115–121.
   Google Scholar
• Miura S, Fujino M, Hanzawa H, . Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J Biol Chem 2006; 281:19288–19295.
   PubMed Web of Science ®Google Scholar
• Miura S, Kiya Y, Kanazawa T, . Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state. Mol Endocrinol 2008; 22:139–146.
   PubMed Web of Science ®Google Scholar
• Yasuda N, Miura S, Akazawa H, . Conformational switch of angiotensin II type 1 receptor underlying mechanical stress-induced activation. EMBO Rep 2008; 9:179–186.
   PubMed Web of Science ®Google Scholar
• Fujino M, Miura S, Kiya Y, . A small difference in the molecular structure of AT1 receptor blockers induces AT1 receptor-dependent and -independent beneficial effects. Hypertens Res 2010; 33:1044–1052.
   PubMed Web of Science ®Google Scholar
• Imai E, Horio M, Watanabe T, . Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol 2009; 13:621–630.
   PubMed Web of Science ®Google Scholar
• Ram CV, Ramaswamy K, Qian C, . Blood pressure outcomes in patients receiving angiotensin II receptor blockers in primary care: a comparative effectiveness analysis from electronic medical record data. J Clin Hypertens. (Greenwich) 2011; 13:801–812.
   PubMed Web of Science ®Google Scholar
• Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001; 3:283–291.
   PubMedGoogle Scholar
• Fabia MJ, Abdilla N, Oltra R, Fernandez C, Redon J. Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens 2007; 25:1327–1336.
   PubMed Web of Science ®Google Scholar
• Brunner HR. Olmesartan medoxomil: current status of its use in monotherapy. Vasc Health Risk Manag 2006; 2:327–340.
   PubMedGoogle Scholar
• Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001; 103:904–912.
   PubMed Web of Science ®Google Scholar
• Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet 2010; 375:906–915.
   PubMed Web of Science ®Google Scholar
• Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109:2054–2057.
   PubMed Web of Science ®Google Scholar
• Clasen R, Schupp M, Foryst-Ludwig A, . PPAR gamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005; 46:137–143.
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Shimada K, Fukuda D, . Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart 2004; 90:528–533.
   PubMed Web of Science ®Google Scholar
• Otsuka F, Sugiyama S, Kojima S, . Plasma adiponectin levels are associated with coronary lesion complexity in men with coronary artery disease. J Am Coll Cardiol 2006; 48:1155–1162.
   PubMed Web of Science ®Google Scholar
• Savchenko A, Imamura M, Ohashi R, . Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol 2008; 215:48–55.
   PubMed Web of Science ®Google Scholar
• Kume N, Mitsuoka H, Hayashida K, Tanaka M. Pentraxin 3 as a biomarker for acute coronary syndrome: comparison with biomarkers for cardiac damage. J Cardiol 2011; 58:38–45.
   PubMed Web of Science ®Google Scholar
• Soeki T, Niki T, Kusunose K, . Elevated concentrations of pentraxin 3 are associated with coronary plaque vulnerability. J Cardiol 2011; 58:151–157.
   PubMed Web of Science ®Google Scholar
• Touyz RM, Savoia C, He Y, . Increased inflammatory biomarkers in hypertensive type 2 diabetic patients: improvement after angiotensin II type 1 receptor blockade. J Am Soc Hypertens 2007; 1:189–199.
   PubMed Web of Science ®Google Scholar
• Persson F, Rossing P, Hovind P, . Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy. Diabetes 2006; 55:3550–3555.
   PubMed Web of Science ®Google Scholar
• Fliser D, Buchholz K, Haller H. EUropean trial on olmesartan and pravastatin in inflammation and atherosclerosis (EUTOPIA) investigators. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110:1103–1107.
   PubMed Web of Science ®Google Scholar
• Prasado K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 2006; 24:33–50.
   PubMedGoogle Scholar
• Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326:1427.
   PubMed Web of Science ®Google Scholar
• Kintscher U, Bramlage P, Paar WD, Thoenes M, Unger T. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol 2007; 6:12.
   PubMed Web of Science ®Google Scholar